Abbott’s Revised Meridia Labeling Adds Renal Precaution
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for Abbott's Meridia (sibutramine) includes a precaution against using the weight-loss drug in patients with mild to moderate renal impairment or renal insufficiency
You may also be interested in...
Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says
Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.
Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says
Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.
Abbott's Meridia To Be Packaged With Patient Guide In 30-Count Bottle
The monthly supply bottles will replace existing 100-count bottles to simplify distribution of the new patient leaflet emphasizing the risk of increased blood pressure and heart rate. Meridia is the fourth of seven drugs flagged by FDA safety officer Graham to have safety information strengthened.